Quality of Life Kinoko Platinum AHCC 750 Mg 60 Ct by Quality of Life

Product Information

I just wanted to give a testimonial about using your wonderful AHCC product. My name is Alina and I have been battling bile duct and liver cancer for the past 4 years. Over those past 4 years and 6 months I have taken your AHCC product daily along with my scheduled weekly conventional chemo and radiation treatments. During this time I have endured the following. 65 chemo treatments and 15 Proton radiation treatments with NO HAIR LOSS. I maintained a great appetite without the use of a doctor prescribed medication to increase my appetite. Blood work continues to be good on a weekly basis and energy level has been good and I am able to take lengthy daily walks of at least 1 hour. Weight has been maintained at a good level. All of the time I know that all of the items mentioned above would not be able without the daily usage of your AHCC product! AHCC continues to be a part of my daily routine and has proven to work for me! (*)" Alina T - Sherman, TX"

AminoUp’s leading supplement, AHCC, was launched in 1987, following an evaluation of more than 100 different mushroom species, and systematically tested for optimized manufacturing. Now, AminoUp has begun a collaboration with the University of Texas Medical Branch, to assess whether AHCC could assist with global efforts to fight the SARS-CoV-2 virus through supporting the immune system. In conclusion, the results from this phase II study demonstrated that AHCC 3 g once daily was effective to support the host immune system to clear persistent HPV infections and was well tolerated with no significant adverse side effects reported. The duration of AHCC supplementation required beyond the first negative result needs more evaluation to optimize durable outcomes based on both HPV infection status and the target IFN-β level. Data Availability Statement The presented bench-to-bedside research provides step-wise data to support the hypothesis that AHCC supplementation modulates host immune system, specifically via suppression of elevated IFNβ levels, to effectively clear chronic, persistent HR-HPV infections. After observing elimination of HR-HPV in vitro in the panel of human cervical cancer cell lines, animal studies were completed that also demonstrated successful, durable elimination of HR-HPV after completing AHCC supplementation. Finally, in two “proof of concept” pilot studies of daily AHCC supplementation successful elimination of HR-HPV was achieved that was durable response. Both the animal and human data suggests the mechanism AHCC supplementation supports the host immune system to clear HPV infections is attributed to the modulation of the expression and signaling of IFNβ that is known to be elevated in chronic viral infections (16, 17). Previously, the two pilot studies evaluating AHCC supplementation in women with persistent HR-HPV infections identified that IFN-β levels of less than 20 pg/ml correlated with the elimination of HR-HPV ( 17). This phase II study confirmed the correlation between suppressed IFN-β levels to less than 20 pg/ml with an increase in T lymphocytes and IFN-γ, which ultimately resulted in clearance of HPV infections in women who received AHCC supplementation. In those patients who were HPV RNA/HPV DNA negative after 6 months of AHCC supplementation but had a mean IFN-β level greater than 20 pg/ml, two remained HPV RNA negative but HPV DNA positive, and three were both HPV RNA and HPV DNA positive 3 months later after supplementation had been stopped. This identified the opportunity for future research to optimize and personalize the duration of supplementation on both HPV infection status and the target IFN-β level. In addition, the data from this study identified the potential opportunity to employ monitoring IFN-β levels, which could be used for both men and women with HPV infections. While this study did focus on women with HR-HPV infections, in the absence of effective testing tools for HPV status in men and with a safety profile comparable to placebo, the use of AHCC supplementation for men with known exposure to HR-HPV (i.e., partners of women with HR-HPV) as well as those with LR-HPV infections could consider AHCC supplementation to clear the HPV infection.Objective: To determine the efficacy, safety, and durability of the use of AHCC supplementation for 6 months to support the host immune system to clear high-risk human papillomavirus (HPV) infections. The AHCC supplement is a proprietary, standardized extract of cultured lentinula edodes mycelia (AHCC ®, Amino Up, Ltd., Sapporo, Japan) that has been shown to have unique immune modulatory benefits. A standardized cultured extract of basidiomycetes (medicinal mushroom) mycelia (roots), AHCC® is one of the world's most researched specialty immune supplements, supported by over 30 human clinical studies. Research on AHCC® has been conducted at some of the finest research institutions worldwide, including highly regarded Ivy League universities. The primary outcome of this trial was to evaluate clearance of persistent high-risk HPV infection determined by HPV DNA-negative test results achieved while receiving AHCC supplementation and maintained for 3, 6, and 12 months post-completion of the AHCC supplementation compared to receiving placebo. At 12 months, after receiving AHCC supplementation for 6 months, if patients were still HPV DNA positive, it was considered a treatment failure or no response (NR), and they went off study. If negative after completion of 6 months of AHCC supplementation and 6 months of placebo, patients continued on study for another 6 months (two visits) to confirm they remained HPV negative and to evaluate the durability of the response. A complete response (CR) was defined as those patients who were HPV RNA and HPV DNA negative at the time of completion of AHCC supplementation and remained HPV RNA and HPV DNA negative throughout the 12 months of follow-up off AHCC supplementation. A partial response (PR) was defined as those patients who were HPV RNA and HPV DNA negative at the time of completion of AHCC supplementation but then tested either HPV RNA or HPV DNA positive at one or more visits in the 12 months of follow-up off AHCC supplementation. Group 2 served as the control for all time points for the duration of the study. Safety and efficacy data were collected in the patients who elected to continue on unblinded AHCC supplementation for 6 months. Sample Collection and Processing

Also in our ADVANCED formula is Fucoidan from Wakame seaweed. This has been shown to work in synergy with the ingredients in this formula.Women must have had 2 other HPV-positive tests with normal/negative cytology, atypical cells, ASCUS, or CIN1 or CIN2 cervical dysplasia JS was a recipient of various unrestricted research grants supporting preclinical studies on AHCC prior to 2014 from Amino Up, Ltd. It is a mouse-model study. Mice are going to be infected with SARS-CoV-2 virus and we will examine the mortality change and other parameters with and without AHCC administration,” says Homma. JS served as principal investigator of the clinical trial and was responsible for study concept, protocol design, data analysis, clinical interpretation of data, writing, and finalization of the manuscript. AG, LM, and BR served as the primary research team responsible for patient screening, clinic visits, sample collection, and analysis and participated in the writing and review of the manuscript. JF served as a clinical collaborator on this study and participated in protocol design, clinical interpretation of data, and final review of the manuscript. JL served as a clinical collaborator on this study and participated in the clinical interpretation of the data and final review of the manuscript. YB served as a research collaborator participating in the interpretation of the sample of analysis, protocol design, and review of the final manuscript. RO served as a research collaborator participating in the interpretation of the sample of analysis and implications for future monitoring assays. He participated in the review and finalization of the manuscript. TB served as a clinical collaborator on this study and participated in protocol design, clinical interpretation of data, and final review of the manuscript. All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication. Funding All patients enrolled were included in safety analysis for adverse events. Overall, no study patients reported greater than grade 1 toxicity on either placebo or the AHCC supplement arm. AHCC was well tolerated compared to placebo.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Publisher’s Note The same team undertook a preliminary clinical study of 10 women, persistently infected with high-risk HPV, that was encouraging enough to lead to a larger clinical trial. Smith is now undertaking a NIH-funded, double-blinded, placebo-controlled study of 50 women with persistent high-risk HPV infection with results expected to be published by 2021.

History of myocardial infarction within past 6 months, unstable angina, CHF, or uncontrolled hypertension (>140/90). Patients with significant medical comorbidities at the discretion of the primary gynecologist. Including immunosuppressive conditions (i.e., HIV+ and rheumatoid arthritis) or taking immune modulation mediations (i.e., immunosuppressants). Although HPV vaccination is effective in the prevention of HPV infections, it has little benefit for the treatment of patients already infected with HPV ( 6). There are very few effective treatment options for eradicating high-risk HPV infections. The objective of current treatment modalities relies upon early detection with routine PAP smear screening and then treatment by the physician employing cryotherapy, surgical excision, loop electrosurgical excision procedure (LEEP), or cold knife conization. These procedures have a higher response rate of 80% to 100%. This local treatment removes the lesion, but patients will frequently have recurrent lesions. Other treatment modalities used for LR-HPV treatment include topical application of podophyllotoxin with up to 40% rate of recurrent lesions or imiquimod with an approximate 15% recurrence ( 7, 8). To date, there is no effective systemic treatment for persistent high-risk HPV infections.